Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $81,000.

  • Silence Therapeutics' Depreciation & Amortization (CF) fell 5.81% to $81,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $311,000, marking a year-over-year decrease of 31.14%. This contributed to the annual value of $336,000 for FY2024, which is 16.00% down from last year.
  • As of Q3 2025, Silence Therapeutics' Depreciation & Amortization (CF) stood at $81,000, which was down 0.00% from $81,000 recorded in Q2 2025.
  • Silence Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $169,607 during Q1 2021, with a 5-year trough of $73,000 in Q1 2025.
  • Over the past 3 years, Silence Therapeutics' median Depreciation & Amortization (CF) value was $86,000 (recorded in 2024), while the average stood at $104,139.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 63.90% in 2021, then surged by 91.70% in 2022.
  • Silence Therapeutics' Depreciation & Amortization (CF) (MRQ) stood at $86,273 in 2021, then soared by 91.70% to $165,383 in 2022, then fell by 15.95% to $139,009 in 2023, then crashed by 45.33% to $76,000 in 2024, then rose by 6.58% to $81,000 in 2025.
  • Its Depreciation & Amortization (CF) was $81,000 in Q3 2025, compared to $81,000 in Q2 2025 and $73,000 in Q1 2025.